OncoMatch/Clinical Trials/NCT07006077
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Is NCT07006077 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Recombinant human IL-21-expressing oncolytic vaccinia virus for advanced pancreatic cancer.
Treatment: Recombinant human IL-21-expressing oncolytic vaccinia virus — The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard therapy
refractory or failed to respond to standard therapy (including disease progression and/or intolerable toxicities)
Cannot have received: systemic anti-tumor treatment
Systemic anti-tumor treatment, including chemotherapy, large-molecule targeted therapy, immunotherapy, and endocrine therapy within 4 weeks before first dose (within 6 weeks of dosing for nitrosourea or mitomycin C)
Cannot have received: small-molecule targeted therapy
Small-molecule targeted therapy within 2 weeks before first dose or within 5 half-lives of the small-molecule targeted drug (whichever is longer)
Cannot have received: traditional Chinese medicine or Chinese herbal medicine used as anti-tumor agent
Traditional Chinese medicine or Chinese herbal medicine used as anti-tumor agent within 2 weeks before first dose
Cannot have received: radiotherapy
Exception: excluding palliative radiotherapy
Radiotherapy (excluding palliative radiotherapy) within 2 weeks before first dose
Cannot have received: oncolytic virus treatment
Prior oncolytic virus treatment
Lab requirements
Blood counts
absolute neutrophil count (ANC) ≥ 1.5×10^9/L, platelet (PLT) count ≥ 75×10^9/L, hemoglobin (Hb) ≥90 g/L (without supportive therapy within 14 days prior to laboratory test)
Kidney function
serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance (Cockcroft-Gault method) ≥45 mL/min
Liver function
serum total bilirubin (TBIL) ≤1.5×ULN (or ≤3×ULN for patients with liver metastasis); AST and ALT ≤3×ULN (or <5×ULN for patients with primary liver cancer or liver metastasis)
Cardiac function
QTc ≤450 ms for males or ≤470 ms for females, NYHA class I, LVEF ≥50%, no severe arrhythmia, no acute coronary syndrome, myocarditis, congestive heart failure, cerebrovascular accidents, or other cardiovascular events of CTCAE (v5.0) grade 3 or higher within 12 months of dosing, no uncontrolled hypertension or hypotension
Required baseline laboratory data include: Hematology: ANC ≥ 1.5×10^9/L, PLT ≥ 75×10^9/L, Hb ≥90 g/L (without supportive therapy within 14 days prior to laboratory test); Liver function: TBIL ≤1.5×ULN (or ≤3×ULN for patients with liver metastasis); AST and ALT ≤3×ULN (or <5×ULN for patients with primary liver cancer or liver metastasis); Renal function: Cr ≤1.5×ULN, and creatinine clearance (Cockcroft-Gault method) ≥45 mL/min; Coagulation: APTT ≤1.5×ULN; INR ≤1.5×ULN. Cardiac: see exclusion criteria for details.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07006077 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-tumor treatment, small-molecule targeted therapy, traditional Chinese medicine or Chinese herbal medicine used as anti-tumor agent disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages